Industry News

First Patient Dose of Glutazumab (GMA102) in the Phase II Clinical Trial for Treatment of Type 2 Diabetes


December 7, 2017, Gmax Biopharm LLC., a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting GPCRs, today announced that it has dosed the first patient in the phase 2 clinical trial of Glutazumab (GMA102) in Australia and New Zealand. Glutazumab is a humanized antibody against GLP-1R for type 2 diabetes and obesity.


The phase 2, randomized, placebo-controlled, double-blinded, semi-sequential dose escalation study, is designed to further evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Glutazumab in Type 2 Diabetes patients.


Top line results of the phase 2 study are expected in mid of 2018.